CalciMedica, Inc.

CALCSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1534133

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$14.5M	$15.9M	$8.3M	$18.9M	$21.0M
Operating Expenses	$24.2M	$38.1M	$14.2M	$35.9M	$29.8M
Operating Income (Loss)	-$24.2M	-$38.1M	-$14.2M	-$35.9M	-$29.8M
Nonoperating Income (Expense)	$10.5M	$3.7M	$6.4M	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$13.7M	—	—	—	—
Income Tax Expense (Benefit)	$1.0K	$1.0K	$1.0K	—	—
Net Income (Loss) Attributable to Parent	-$13.7M	-$34.4M	-$7.8M	-$35.8M	-$27.5M
Earnings Per Share, Basic	-$1.22	-$7.66	-$111.16	-$1.69	—
Earnings Per Share, Diluted	-$1.22	-$7.66	-$111.16	-$1.69	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$19.8M	$12.2M	$3.3M	$69.1M	$101.8M
Assets, Current	$19.7M	$11.6M	$1.7M	$67.1M	$99.2M
Cash and Cash Equivalents, at Carrying Value	$7.9M	$5.5M	$1.3M	$13.4M	$33.4M
Liabilities	$5.4M	$4.0M	$12.6M	$4.1M	$7.0M
Liabilities, Current	$3.7M	$4.0M	$4.8M	$4.1M	$7.0M
Accounts Payable, Current	$2.0M	$1.4M	$2.9M	$527.0K	$2.5M
Stockholders' Equity Attributable to Parent	$8.2M	-$71.3M	-$64.0M	$94.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$21.1M	-$25.7M	-$11.8M	-$31.5M	-$32.1M
Net Cash Provided by (Used in) Investing Activities	-$4.4M	$8.9M	-$4.0K	$10.8M	-$42.6M
Net Cash Provided by (Used in) Financing Activities	$28.0M	$20.9M	$8.5M	$695.0K	$92.2M
Payments to Acquire Property, Plant, and Equipment	$8.0K	$78.0K	$4.0K	$488.0K	$1.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)